An 8-wk growth trial was conducted to assess the effects of continuous infusion of thyrotropin-releasing hormone (TRH) and an active TRH analog <Aad-His-Pro-NH2 (the <Aad is L-pyro-a-aminoadipic acid) on growth trial performance, carcass composition and hormone profiles of growing lambs. Both drugs were infused at 600 /If'lamb -1 .d -1 with 16 lambs/treatment. Both TRH and <Aad-His-Pro-NH2 decreased average daily gain (ADG; P<.(H) and increased feed conversion (FC; P<.01) compared with saline infused controls.. Average daily feed intake was not altered. Carcasses of lambs given TRH or <Aad-His-Pro-NH2 contained fewer kilograms of moisture (P<.05) and appeared to contain fewer kilograms of protein. Thyrotropin-releasing hormone and <Aad-His-Pro-NH= increased thyroid gland weights (P<.05), but pituitary gland weights were not different. Plasma thyrotropin (TSH) concentrations were increased by both drugs compared with control lambs, peaking at 4 to 7 d after initiating infusion. However, by 14 d, TSH concentrations returned to control levels. Triiodothyronine (T3) and thyroxine (T4) were elevated by both drugs over the entire 8-wk trial, with peak levels reached at 10 d and maintained for the duration of the study. Both TRH and <Aad-His-Pro-NH 2 increased prolactin over the entire period. Growth hormone levels were not altered by either drug. The effects of <Aad-His-Pro-NH~ infusion on growth trial performance, carcass composition and hormone profiles of growing lambs were Dept. of Anim. Nutr. and Physiol. 2The authors express their appreciation to Paul Duquette and Eric Rickes for their technical assistance and to Dr. Martin Hichens for preparing 12Si_labeled hormones.
Introduction
Thyrotropin-releasing hormone (TRH), given by iv injection, increased plasma concentrations of prolactin (PRL) and thyrotropin (TSH) in sheep and cattle (Davis et al., 1976; Davis et al., 1977b) . In addition, TRH elevated plasma concentrations of triiodothyronine (T3) and thyroxine (T4) in these species (McGuffey et al., 1977; Johke, 1978; Ohlson et al,, 1978; Klein and Fisher, 1980) . The effects of TRH on plasma concentrations of growth hormone (GH) appear inconsistent, with some researchers reporting an increase in cattle (Convey et al., 1973; McGuffey et al., 1977) and others reporting no consistent effect in cattle (Davis et al., 1977b) or sheep (Klindt et al., 1979) .
Chronic sc injections of TRH increased the average daily gain (ADG) and average daily feed intake (ADF) of lambs (Davis et al., 1976; Davis et al., 1977a) and cattle (Davis et al., 1977b; McGuffey et al., 1977) . Feed conversion (FC) was not improved significantly in any of these trials. More recently, Klindt et al. (1979) reported that TRH, infused constantly for 5 d, greatly increased plasma levels of TSH and PRL, but not GH. The objective of this study was to determine the effects of continuous infusion of TRH and an active TRH analog for 8 wk on the hormone profiles and the performance and carcass characteristics of growing lambs.
one-half ewes and one-half wethers, were used in an 8-wk growth trial to evaluate the effects of chronic administration of TRH and an active TRH analog. Lambs, with an average initial weight of 35.2 kg, were randomized to treatments according to weight and sex. Because there were three treatments and Iambs were housed two/pen, each treatment contained four pens of two wethers and four pens of two ewes. Lambs were fed diet B-1 (table 1) , shorn and adapted to pens for 2 wk. Feed, salt and fresh water were available ad libitum. During the growth trial, individual lamb weights and feed consumed/pen were determined every 2 wk. Initial and final body weights were determined by weighings on 2 consecutive days. At the end of the trial, all lambs were necropsied and empty carcasses (whole body minus head, legs from the carpal and tarsal joints, gastrointestinal tract and internal organs), including pelts, were ground. Aliquots of ground carcass were stored at -20 C for analyses of moisture, protein and fat. Pituitary and thyroid glands were weighed.
Treatments and Blood Sampling. The treatments included control (saline), TRH 3 and the TRH analog <Aad-His-Pro-NH2 (the <Aad is L-pyro-a-aminoadipic acid) 3 infused at 600 /~g'lamb-l"d -t. Alzet osmotic minipumps 4, used to administer the drugs, were filled with saline or a 50 mg/ml solution of TRH or <Aad-His-Pro-NH2 in saline. The osmotic minipumps contained 170 ~1 and pumped at a rate of .5 /ll/h, giving a dose of 25/ag/h. Minipumps were implanted sc above the third rib slightly to the right of the dorsal midline. New minipumps were implanted every 12 d for the duration of the trial.
All lambs were bled two times at 30-rain intervals before the minipumps were implanted (d 0) and again on the final day of the 8-wk trial. In addition, 12 lambs (two'sex -l .treatment -1) were designated for blood sampling and bled on d 0, 4, 7, 10, 14, 28, 42 and 56 at 15-rain intervals from 0900 to 1030 h. Plasma samples COn an as-fed basis according to laboratory analysis.
were stored frozen at -20 C for analyses of GH, PRL, TSH, T3 and T4 by radioimmunoassay (RIA).
Hormone Assays. Plasma TSH was determined using the double antibody radioimmunoassay (RIA) procedure of Borger and Davis (1974) . Antiserum was a gift from Dr. S. L. Davis s and the ~subunit of bTSH (30 to 40 IU/mg) used for iodination was a gift from Dr. J. G. Pierce 6. The reference standard was NIH-TSH-S7 (3.87 USP units/rag) 7. Assay sensitivity was .5 ng/ml. Plasma PRL and GH were determined using double antibody R1A procedures similar to the procedures of Davis et al. (1971) for PRL and Davis (1972) for GH. Procedure modifications for the GH and PRL assays were identical. After first antibody addition, samples were incubated at 37 C for 4 to 6 h. Next, labeled hormone was added and tubes were incubated at 37 C for an additional 18 h. Finally, a second antibody was added and samples were incubated at 4 C for 24 h. Both PRL and GH antisera were developed and evaluated by Dr. M. Hichens s. Both antisera were produced in rabbits using the methods of Niswender et al. (1968) . The hormones used to produce the antisera were NIH-P-S10 (25.6 IU/mg) ~ and NIH-GH-S10 (.86 IU/mg) 7. The PRL antiserum did not cross-react (<.03%) with FSH (NIH-FSH-Sll, 1.15 NIH-FSH-S1
units/mg) 7, LH (NIH-LH-S19, 1.01 NIH-LH-S1 units/mg) ~ or TSH (NIH-TSH-S7). The PRL antiserum was also tested against two GH sources (oGH-LER-9/214, .82 IU/mg 9 and bGH, 1.5 Iu/m~g). The bGH was a gift from Dr. S. L. Steelman . The oGH-LER-9/214 and the bGH did exhibit a small degree of reactivity with the PRL antiserum (.34 and .16%, respectively), which corresponded to the known PRL contaminations in these preparations. The GH antiserum did not cross-react (<.2%) with FSH (NIH-FSH-S11), LH (NIH-LH-S19), TSH (NIH-TSH-S7) or PRL (NIH-P-Sll). The hormones used for iodination were NIH-P-S11 (26 IU/mg) 7 and bGH (1.5 IU/mg). The reference standards were NIH-GH-S10 and NIH-P-S12 (35 IU/mg) 7. Assay sensitivities were 1 ng/ml for PRL and .5 ng/ml for GH. Plasma levels of T3 and T4 were determined by RIA procedures using commercial kits 1~ Assay sensitivities were 10 ng/100 ml for T3 and 1/ag/100 ml for T4.
Carcass Analyses. Frozen carcass samples
were reground and moisture, fat and N contents were determined by New Jersey Feed Laboratory, Incorporated x2 according to AOAC (1980) procedures.
Statistical Analyses. Performance data, including average daily gain (ADG), average daily feed intake (ADF) and feed conversion (FC), carcass data, including moisture, protein and fat, and gland weights were analyzed for treatment and sex effects by least-squares analyses of variance (Harvey, 1960) using initial body weight as a covariant. Plasma hormone data from all lambs at the end of the 8-wk trial were averaged (two samples/lamb) and averages were analyzed for treatment and sex effects by least-squares analyses of variance (Harvey, 1960) using initial hormone levels (average of two samples/lamb) as the covariant. Plasma hormone data from each of the 12 lambs bled during the trial were averaged for each sampling day (seven samples'lamb -l "d-l). These animal averages were used to estimate treatment means (four lambs/treatment) for each sampling day 
Results and Discussion
The dose of 600/ag/d used in this study was selected on the basis of a preliminary 14-d infusion in lambs where TRH at at 600/~g/d, but not 100 /ag/d, increased plasma levels of both PRL and TSH. Plasma PRL was increased 110% by the higher dose of TRH on both d 6 and 14 while plasma TSH was increased 786% on d 6, but only 10% on d 14. The lower dose increased TSH, but not PRL. These results were similar to those reported by Klindt et al. (1979) , who infused TRH at 500 and 100/ag/d for 5 d in lambs using Alzet osmotic minipumps and observed TSH responses at both doses, while PRL was only elevated at the greater dose. The TRH analog <Aad-His-Pro-NH2 has been described previously (Nutt et al., 1981) and was selected for evaluation on the basis of preliminary studies with lambs that indicated that <Aad-His-Pro-NH2 was at least as effective as TRH in elevating plasma PRL and TSH following stat doses given iv (data not shown).
Control lambs gained .27 kg/d, ate 1.83 kg of feed/d and had an FC value of 6.78 (table 2) . Ewe lambs gained less (.21 vs .26 kg/d; P<.01) and ate less (1.71 vs 1.94 kg/d; P<.10) than wether lambs, but FC values were similar (8.18 vs 7.53 for ewes and wethers). Both TRH and <Aad-His-Pro-NH2 reduced the performance of ewe and wether lambs with no indication of a treatment by sex interaction. Thyrotropinreleasing hormone and <Aad-His-Pro-NH2 decreased (P<.01) ADG 21 and 15%, respectively, compared with saline-infused controls (table 2) . Also, TRH and <Aad-His-Pro-NH2 increased (P<.01) FC (i.e., the amount of feed required to produce a unit of gain) 26 and 22%, respectively. Neither drug significantly affected ADF. These results with TRH are not in agreement with those reported by Davis et al. (1976 Davis et al. ( , 1977a in lambs or by Davis et al. (1977b) and McGuffey et al. (1977) in calves. In the latter studies, regular injections of TRH caused increases in ADG and ADF of approximately 8 to 10% for both lambs and calves with no effect on FC. However, only McGuffey et al. (1977) reported these increases in ADG and ADF to be significant. Differences in growth performance between the present study and those reported by Davis et al. (1976 Davis et al. ( , 1977a Plasma TSH, T3 and T4 concentrations of the control lambs, selected for bleeding, changed very little during the 8-wk trial (figure 1). Both TRH and <Aad-His-Pro-NH2 increased TSH in lambs during the first 2 wk of infusion, with peak TSH levels reached at 4 to 7 d. However, by 14 d, TSH in lambs infused with these drugs returned to control levels and stayed at these levels for the remainder of the experiment. Both T 3 and T4 were elevated over the entire 8-wk trial by TRH or <Aad-His-Pro-NH2 infusion. Both T3 and T4 reached peak levels 10 d after the initiation of drug infusion. Blood samples, taken at the end of the trial from all lambs, had similar TSH levels (5.6 ng/ml) regardless of treatment (table 5) . Lambs infused with TRH or <Aad-His-Pro-NH2 had greater T3 (P<.05) and T4(P<.05) levels at 8 wk. At 8 wk, lambs given TRH had greater T3 levels than bLeast-squares means using initial body weight as a eovariant.
X'YValues in the same column with different superscripts differ (P<.05). Plasma PRL levels of control lambs increased during the last 4 wk of the trial (figure 2). Because the trial started in January and ended in March, these changes in PRL levels of control lambs are most likely the result of increased ambient temperature (Tucker and Wettemann, 1976) and photoperiod (Leining et al., 1979) . Plasma GH concentrations of control lambs were variable, but appeared to decrease over the first 2 wk and then remained stable over the remainder of the trial. Both TRH and <Aad-HisPro-NH2 increased PRL levels, but not GH, during the 8-wk trial,. The PRL responses to drug infusion were greatest during the last one-half of the trial. This increased response is probably the result of the higher ambient temperature because increasing ambient temperature has been shown to enhance PRL response to TRH (Tucker and Wettemann, 1976) . Similar effects of drug infusion on PRL were observed at the end of the trial in blood samples from all lambs (table 5) . Both TRH and <Aad-His-Pro-NH2 increased PRL at 8 wk (P<.05) and lambs given <Aad-His-Pro-NH2 had greater PRL levels than lambs given TRH (501 vs 310 ng/ml; P<.05), but GH was not altered by either drug. Ewe and wether lambs had similar PRL and GH values at 8 wk (data not shown).
Increases in plasma TSH and PRL in lambs and calves following TRH injection during a period of chronic TRH administration have been observed previously (Davis et al., 1976 (Davis et al., , 1977b . The effects of TRH administration on plasma GH have not been consistent. Some investigators have reported elevated GH following TRH administration (Convey et al., 1973; McGuffey et al., 1977; Johke, 1978) . Other investigators observed no consistent effect (Davis et al., 1976 (Davis et al., , 1977b Ohlson et al., 1978) . Administration of TRH to lambs and calves has also been reported previously to increase plasma T3 (Johke, 1978; Ohlson et al., 1978) and T4 (McGuffey et al., 1977; Ohlson et al., 1978; Klein and Fisher, 1980) . In the only long-term infusion study reported previously, Klindt et al. (1979) used Alzet osmotic minipumps to infuse 500 #g/d into ewe lambs for 5 d. They observed increased TSH and PRL levels during the infusion period. Thus, the effects of TRH infusion on plasma PRL, TSH, GH, T3 and T4 in the present study are consistent with the reported results following chronic injection, with the possible exceptions of GH and TSH.
The reasons for the inconsistencies in GH response to TRH are not known. However, most of the studies, where a positive GH bLeast-squares means using initial hormone level as a covariant.
x'Y'ZValues in the same column with different superscripts differ (P<.05).
response to TRH has been observed, were in cattle (Convey et al., 1973; McGuffey et al., 1977; Johke, 1978) and most of the cases where TRH failed to cause a GH response, including this study, were in sheep (Davis et al., 1976; Klindt et al., 1979) . One exception was a report by Davis et al. (1977b) , where twice daily injections did not elicit a significant GH response in Holstein heifers. Plasma T3 and T4 remained elevated in this study despite the return of plasma TSH to normal levels after 10 d of TRH or <Aad-HisPro-NH2 infusion. A hypothesis to explain these observations is that the initial elevation of TSH caused the growth of the thyroid gland (Burgi and Labhart, 1974) . The enlarged thyroid gland produced more T 4 (and T3) which, in turn, partially inhibited the secretion of TSH by the pituitary gland (Burgi and Labhart, 1974) . The enlargement of the thyroid glands persisted through the remainder of the trial (102 and 70% increases in thyroid gland weights for TRH-and <Aad-His-Pro-NH2-infused lambs, respectively) and accounted for the continued elevation of T3 and T4. This hypothesis is supported by the observation that the amounts of plasma T4 (or T3) per gram of thyroid tissue at the end of the trial were similar across treatments (ratios calculated from data in tables 4 and 5).
The negative effects of thyroid hormones on skeletal muscle (Burman et al., 1979; Goldberg et al., 1980) and growth (Burgi and Labhart, 1974; Godden and Weekes, 1981) are well established. Minimal levels of T3 or T4 are essential for normal growth of muscle; however, above normal levels of T3 or T4 enhance muscle protein catabolism (Burman et al., 1979; Goldberg et al., 1980) . Godden and Weekes (1981) observed a negative correlation between ADG and T4 levels in lambs where T4 was elevated by exogenous TSH administration. On the other hand, Kahl et al. (1978) reported that plasma T4 levels were 11% higher in steers implanted with estrogen and progesterone (Synovex-S). This elevation in T4 occurred during the first 60 d of a 120-d trial when gains were increased 19% by hormone treatment, but did not occur during the second one-half of the trial when gain was increased 30% compared with nonimplanted controls. Plasma T3 levels were not altered. The elevation in plasma T4 observed by Kahl et al. (1978) may be the result of estrogen and progesterone implants, but may not be associated with the greater rates of gain because increased gains also occurred during the second one-half of their trial without a concomitant increase in plasma T4. In the present study, the negative effects of TRH and
